CURE — DIREXION SHS ETF TR
As of Q2 2026, 5 SEC-registered investment managers reported holding CURE (DIREXION SHS ETF TR) in their latest 13F filings, with a combined reported value of $15.50M across 138.16K shares. That is +98.2% by share count (+68.46K shares) versus the previous quarter, while reported value moved +142.8%. Ownership is concentrated: the five largest holders account for 100.0% of reported value and the top ten for 100.0%.
Compared with the prior quarter, 2 opened new positions, 1 added to existing stakes. 13F holdings are quarter-end snapshots, so these moves reflect positioning as of Q2 2026, not real-time trading.
All figures on this page are computed from SEC Form 13F quarterly filings. 13F filers disclose long positions of $100,000 or more within 45 days of quarter end; short positions, options overlays and intra-quarter trades are not included, so treat the numbers as a quarterly snapshot of institutional ownership rather than real-time positioning.
Q2 2026 — 5 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| Citadel Advisors history | 96.00K | $10.77M | 0.00% | Add |
| Goldman Sachs Group history | 41.16K | $4.62M | 0.00% | New |
| UBS Group AG history | 999 | $112.06K | 0.00% | New |
| Morgan Stanley history | 1 | $141 | 0.00% | Hold |
| Wells Fargo & Co history | 1 | $105 | 0.00% | Hold |
Q1 2026 — 3 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| Citadel Advisors history | 69.70K | $6.38M | 0.00% | Add |
| Morgan Stanley history | 1 | $152 | 0.00% | New |
| Wells Fargo & Co history | 1 | $46 | 0.00% | Hold |
Q4 2025 — 3 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| Citadel Advisors history | 54.91K | $6.13M | 0.00% | Add |
| UBS Group AG history | 418 | $46.63K | 0.00% | Add |
| Wells Fargo & Co history | 1 | $130 | 0.00% | Hold |
Q3 2025 — 4 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| Citadel Advisors history | 50.18K | $4.19M | 0.00% | Reduce |
| UBS Group AG history | 257 | $21.46K | 0.00% | Add |
| Morgan Stanley history | 1 | $123 | 0.00% | Reduce |
| Wells Fargo & Co history | 1 | $65 | 0.00% | Hold |
Q2 2025 — 4 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| Citadel Advisors history | 53.77K | $4.24M | 0.00% | Add |
| Morgan Stanley history | 456 | $35.97K | 0.00% | Add |
| UBS Group AG history | 1 | $79 | 0.00% | Reduce |
| Wells Fargo & Co history | 1 | $73 | 0.00% | New |
Q1 2025 — 4 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| Citadel Advisors history | 41.92K | $4.47M | 0.00% | Add |
| UBS Group AG history | 5.15K | $549.36K | 0.00% | Add |
| PNC Financial Services history | 600 | $63.97K | 0.00% | New |
| Morgan Stanley history | 212 | $22.61K | 0.00% | Reduce |
New Positions (Q2 2026)
- Goldman Sachs Group 41.16K sh · $4.62M
- UBS Group AG 999 sh · $112.06K
Fully Exited (vs previous quarter)
No tracked fund fully exited this quarter.
Fund Position History — shares by quarter (top 10 funds)
| Fund | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Citadel Advisors | 96.00K | 69.70K | 54.91K | 50.18K | 53.77K | 41.92K | 36.31K | 14.47K | 49.73K | 53.66K | 53.90K | 61.48K | 43.94K | 48.71K | 14.16K | 18.70K | 23.10K | 31.79K | 30.99K | 47.01K |
| Goldman Sachs Group | 41.16K | — | — | — | — | — | — | — | — | — | — | 37.52K | 19.80K | 3.80K | — | — | — | 6.29K | — | — |
| UBS Group AG | 999 | — | 418 | 257 | 1 | 5.15K | 309 | — | 1.07K | — | 203 | 519 | 15 | — | — | 137 | — | — | — | 256 |
| Morgan Stanley | 1 | 1 | — | 1 | 456 | 212 | 921 | 587 | 4 | 1 | 510 | 153 | 431 | 503 | 160 | 151 | 387 | 319 | 1.81K | 1.92K |
| Wells Fargo & Co | 1 | 1 | 1 | 1 | 1 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Fidelity Management & Research (FMR) | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 1 | — | 1 | — | — | — |
| Renaissance Technologies | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 3.60K | — |
| Bank of America Corp | — | — | — | — | — | — | — | — | — | 120 | — | — | — | — | — | — | — | — | — | 300 |
| Citigroup Inc | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 300 | 300 | 300 | 400 |
| PNC Financial Services | — | — | — | — | — | 600 | — | — | — | — | — | — | — | — | — | — | 3 | — | — | — |
▲ Bought Low (fund opened/added, stock rose ≥5% next quarter) ▼ Sold High (fund reduced, stock fell ≥5% next quarter)
Drag / scroll to zoom · Default shows the most recent year · Annotations come from quarterly fund actions in 13F filings · Hover a marker for details